Soleno Therapeutics, Inc. (SLNO)
Automate Your Wheel Strategy on SLNO
With Tiblio's Option Bot, you can configure your own wheel strategy including SLNO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: April 03, 2026 by: PRNewsWire
Sentiment: Neutral
BENSALEM, Pa., April 3, 2026 /PRNewswire/ -- The Law Offices of Howard G.
Read More
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: April 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, April 03, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. (“Soleno” or “the Company”) (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 26, 2025 and November 4, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before May 5, 2026.
Read More
SLNO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
Published: April 03, 2026 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 3, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Soleno Therapeutics, Inc. ("Soleno" or the "Company") …
Read More
Soleno (SLNO) Sued After DCCR Launch Setback, Share Drop-- Hagens Berman
Published: April 01, 2026 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking to represent investors who purchased Soleno common stock between March 26, 2025 and November 4, 2025. The lawsuit follows Soleno's November 5, 2025 report of disappointing information about DCCR (trademarked as VYKAT™ XR), a once-daily oral tablet intended to treat hyperphagia.
Read More
SLNO Stockholders Have Rights – If You Lost Money Investing in Soleno Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
Published: March 31, 2026 by: GlobeNewsWire
Sentiment: Neutral
Robbins LLP is Investigating Allegations that Soleno Therapeutics SLNO Misled Investors Regarding the Viability and Efficacy of its Phase 3 Clinical Trial
Read More
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Soleno Therapeutics, Inc. (SLNO)
Published: March 31, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - March 31, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the common stock of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO) between March 26, 2025 and August 4, 2025, inclusive. Should You Join The Soleno Class Action Lawsuit?
Read More
Deadline Alert: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Published: March 30, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 30, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2026, inclusive (the “Class Period”).
Read More
Soleno Therapeutics, Inc. (SLNO) Class Action Lawsuit Seeks Recovery for Investors: May 5, 2026, Deadline – Contact Kessler Topaz Meltzer & Check, LLP
Published: March 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
Did you buy SLNO common stock between March 26, 2025, and November 4, 2025? Affected Soleno Therapeutics, Inc. Investor Summary Who: Soleno Therapeutics, Inc. (NASDAQ: SLNO) What: Securities fraud class action lawsuit filed Class Period: March 26, 2025, through November 4, 2025 Deadline to Seek Lead Plaintiff Status: May 5, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's Phase 3 clinical trial program for diazoxide choline extended-release tablets (“DCCR”).
Read More
Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman
Published: March 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, March 27, 2026 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking to represent investors who purchased Soleno common stock between March 26, 2025 and November 4, 2025. The lawsuit follows Soleno's November 5, 2025 report of disappointing information about DCCR (trademarked as VYKAT™ XR), a once-daily oral tablet intended to treat hyperphagia.
Read More
SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit — The Gross Law Firm
Published: March 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO).
Read More
SLNO INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
Published: March 27, 2026 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - March 27, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Soleno Therapeutics, Inc. ("Soleno" …
Read More
SLNO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
Published: March 25, 2026 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their Options
Read More
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: March 24, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 24, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. (“Soleno” or “the Company”) (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 26, 2025 and November 4, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before May 5, 2026.
Read More
Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman
Published: March 24, 2026 by: PRNewsWire
Sentiment: Neutral
SLNO Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, March 24, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking to represent investors who purchased Soleno common stock between March 26, 2025 and November 4, 2025. The lawsuit follows Soleno's November 5, 2025 report of disappointing information about DCCR (trademarked as VYKAT™ XR), a once-daily oral tablet intended to treat hyperphagia.
Read More
Soleno Therapeutics, Inc. (SLNO) Investors: May 5, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Published: March 23, 2026 by: GlobeNewsWire
Sentiment: Neutral
Did you buy SLNO common stock between March 26, 2025, and November 4, 2025? Affected Soleno Therapeutics, Inc. Investor Summary Who: Soleno Therapeutics, Inc. (NASDAQ: SLNO) What: Securities fraud class action lawsuit filed Class Period: March 26, 2025, through November 4, 2025 Deadline to Seek Lead Plaintiff Status: May 5, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's Phase 3 clinical trial program for diazoxide choline extended-release tablets (“DCCR”).
Read More
Deadline Alert: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Published: March 23, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 23, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2026, inclusive (the “Class Period”).
Read More
Bronstein, Gewirtz & Grossman LLC Urges Soleno Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Published: March 23, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Soleno securities between March 26, 2025 and November 4, 2025, both dates inclusive (the “Class Period”).
Read More
Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman
Published: March 23, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, March 23, 2026 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking to represent investors who purchased Soleno common stock between March 26, 2025 and November 4, 2025. The lawsuit follows Soleno's November 5, 2025 report of disappointing information about DCCR (trademarked as VYKAT™ XR), a once-daily oral tablet intended to treat hyperphagia.
Read More
NASDAQ: SLNO: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Soleno Therapeutics, Inc.
Published: March 20, 2026 by: PRNewsWire
Sentiment: Neutral
Did you buy SLNO common stock between March 26, 2025, and November 4, 202 5? Affected Soleno Therapeutics, Inc. Investor Summary Who: Soleno Therapeutics, Inc. (NASDAQ: SLNO) What: Securities fraud class action lawsuit filed Class Period: March 26, 2025, through November 4, 2025 Deadline to Seek Lead Plaintiff Status: May 5, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's Phase 3 clinical trial program for diazoxide choline extended-release tablets ("DCCR").
Read More
SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
Published: March 20, 2026 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - March 20, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Soleno Therapeutics, Inc. ("Soleno" …
Read More
Bronstein, Gewirtz & Grossman LLC Urges Soleno Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Published: March 19, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Soleno securities between March 26, 2025 and November 4, 2025, both dates inclusive (the “Class Period”).
Read More
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Soleno Therapeutics, Inc. (SLNO)
Published: March 19, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - March 19, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the common stock of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO) between March 26, 2025 and August 4, 2025, inclusive. Should You Join The Soleno Class Action Lawsuit?
Read More
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: March 18, 2026 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES, March 18, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO) have opportunity to lead the securities fraud class action lawsuit.
Read More
INVESTOR DEADLINE: Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD Law
Published: March 18, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, March 18, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025, inclusive (the “Class Period”), have until May 5, 2026 to seek appointment as lead plaintiff of the Soleno class action lawsuit. Captioned City of Pontiac Police and Fire Retirement System v.
Read More
SLNO CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
Published: March 18, 2026 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their Options
Read More
Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman
Published: March 18, 2026 by: PRNewsWire
Sentiment: Neutral
SLNO Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, March 18, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking to represent investors who purchased Soleno common stock between March 26, 2025 and November 4, 2025. The lawsuit follows Soleno's November 5, 2025 report of disappointing information about DCCR (trademarked as VYKAT™ XR), a once-daily oral tablet intended to treat hyperphagia.
Read More
INVESTOR NOTICE: Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit filed by Robbins Geller Rudman & Dowd LLP
Published: March 09, 2026 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)---- $SLNO #SLNO--The Soleno complaint alleges that Soleno Phase 3 clinical trial program for DCCR had downplayed, misrepresented, and/or concealed safety concerns.
Read More
INVESTOR NOTICE: Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit filed by Robbins Geller Rudman & Dowd LLP
Published: March 09, 2026 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)---- $SLNO #SLNO--The Soleno complaint alleges that Soleno Phase 3 clinical trial program for DCCR had downplayed, misrepresented, and/or concealed safety concerns.
Read More
Down 18.3% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Positive
The heavy selling pressure might have exhausted for Soleno Therapeutics (SLNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read More
Soleno Therapeutics (SLNO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Published: January 14, 2026 by: Zacks Investment Research
Sentiment: Positive
After losing some value lately, a hammer chart pattern has been formed for Soleno Therapeutics (SLNO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Read More
About Soleno Therapeutics, Inc. (SLNO)
- IPO Date 2014-11-13
- Website https://soleno.life
- Industry Biotechnology
- CEO Anish Bhatnagar
- Employees 115